A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced NSCLC Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029

Trial Profile

A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced NSCLC Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel; Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 05 Jun 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 22 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top